FDA Panel Explores Nocturnal Hemodialysis Device, Trial Design
This article was originally published in The Gray Sheet
FDA's Gastroenterology & Urology Devices Panel emphasized the importance of human factors considerations for nocturnal hemodialysis devices during a June 8 meeting in Gaithersburg, Md
You may also be interested in...
An April 15 FDA guidance tells makers of nocturnal home hemodialysis systems what sorts of clinical trials they should perform to smooth the FDA pre-market clearance process
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.